Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE

Simple imaging biomarker predicts survival in anal squamous cell cancer treated with curative intent: a UK cohort study.

“…This is consistent with previous data showing failure to achieve complete response results in poorer survival, irrespective of whether complete response was assessed clinically (Glynne-Jones, Sebag-Monte ore et al 2017)), by PET(Adusumilli, Elsayed et al 2022) or MRI(Adusumilli, Elsayed et al 2022). Whilst variable incidence of complete response (61.3-88%)(Glynne-Jones, Sebag-Monte ore et al 2017),(Adusumilli, Elsayed et al 2022),(Martin, Schreckenbach et al 2022),(Vendrely, Lemanski et al 2023) is reported, assessed by both clinical and imaging methods, our mrCR rate is comparable to other studies(Glynne-Jones, Sebag-Monte ore et al 2017),(Martin, Schreckenbach et al 2022), so reassuring for the data validity. Our ndings support the use of MRI as the method of assessing for complete response, identifying similar incidence of endoluminal complete response as reported by ACT II but with the bene t of being able to assess for extramural disease.…”

“…There has been a widespread adoption of MRI for the staging of anal SCC; 71.2% of patients in the French FFCD-ANABASE cohort study underwent pelvic MRI at initial workup (Vendrely, Lemanski et al 2023) and high-resolution MRI imaging is recommended for staging by international guidelines(The Royal College of Radiologists 2014), (Rao, Guren et al 2021). It is assumed, although not proven, that MRI is utilised to assess TNM staging based on the length of the tumour rather than the depth of the tumour (unless there is T4 disease and therefore, by de nition, evidence of invasion into an adjacent structure(American Joint Committee on Cancer (AJCC) 2017)).…”

Reduction of elective lymph node volume in radiotherapy of early anal squamous cell cancer: a comparative study between two Swedish university hospitals

“…For instance, the patients were not staged with MRI or PET-CT, and RT was delivered with static fields. The DFS (55%) and OS (69%) at 5 years is much lower compared with what is reported from more recent studies[1,2,13]. A similar, but smaller Australian study from 2018 reported the oncologic outcome in 51 patients treated with different RT volumes at a single centre[1994][1995][1996][1997][1998][1999][2000][2001][2002][2003][2004][2005][2006][2007]…”

“…Anal squamous cell cancer (ASCC) in early stages (T1-2N0M0, UICC TNM7) is treated with radiotherapy (RT) with addition of chemotherapy in most cases (chemoradiotherapy; CRT). Recent cohort studies indicate a 3-year disease free survival (DFS) of 84-85% and an overall survival (OS) of 92% in early ASCC treated with RT alone or CRT [1,2]. The risk of local recurrence in early ASCC treated with CRT is low and has been reported in 5.4% of the patients [2].…”

Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial

“…Our study present different limitations: the 3cm size cut-off could be questionable to define locally advanced tumors, however we chose this cut-off according to the ACCORD-16 study, which tested cetuximab in addition to radiotherapy and concurrent chemotherapy with CDDP and 5FU (13). Moreover, in the FFCD-ANABASE cohort, a 3 cm-size was identified as a prognostic/predictive factor (31).…”